

# Subject Index

- Adipokines**  
adiponectin, 1101  
chemerin, 1101  
connective tissue diseases, 1101  
leptin, 1101  
resistin, 1101  
visfatin, 1101
- Adult-onset Still's disease**  
18F-fluoro-deoxyglucose positron emission tomography/computed tomography, 566  
biological agents, (Suppl. 102) S-64  
interleukin-6, (Suppl. 102) S-64  
refractory, (Suppl. 102) S-64  
spleen biopsy, 566  
tocilizumab, (Suppl. 102) S-64
- Anakinra**  
biologics, 531  
infections, 531  
infectious risk, 531  
tuberculosis, 531
- ANCA-associated vasculitis**  
azathioprine, (Suppl. 97) S-54  
health-related quality of life, (Suppl. 97) S-54  
maintenance therapy, (Suppl. 97) S-54  
rituximab, (Suppl. 97) S-54
- Animals (B01)**  
Animals (B01), (Suppl. 98) S-6
- Ankylosing spondylitis**  
acute-phase reactants, 100  
ankylosing spondylitis, (Suppl. 98) S-69  
antirheumatic agents, 698  
anti-TNF, 184  
anti-TNF therapy, 94  
ASAS, (Suppl. 95) S-7  
ASASBIO, 94  
ASDAS-CRP, 94  
axial spondyloarthritis, (Suppl. 95) S-7  
BASDAI, 94  
BASF, 94  
biological products, 975  
biosimilar pharmaceuticals, 698  
bone density, 191  
cardiovascular disease, 885  
carotid ultrasonography, 885  
classification, (Suppl. 95) S-5, S-7  
clinical protocols, 592  
CT-P13, 698  
cytokines, 100  
diagnosis, (Suppl. 95) S-5  
ELISA, 155  
etoricoxib, 94  
high mobility group box chromosomal protein 1 (HMGB1), 155  
incidence, 191  
inflammatory bowel disease, 214  
infliximab, 184  
juvenile onset, 668  
modified Stoke AS Spinal Score, 668  
mononuclear cells, 100  
MRI, (Suppl. 95) S-5  
non-radiographic, (Suppl. 95) S-7  
open label, 94  
outcome measures, 214  
psoriasis, 214  
quality of life, 975  
safety, 94  
satisfaction, 94  
suppressors of cytokine signaling (SOCS), 100  
spinal fracture, 191  
systematic coronary risk evaluation (SCORE), 885  
therapeutic equivalence, 698  
TNFR-Fc fusion protein, 592  
tumour necrosis factor-alpha blocking therapy, 191  
ultrasonography, 885  
uveitis, 214
- Antineutrophil cytoplasmic antibodies**  
gastrointestinal, (Suppl. 95) S-25  
glomerular crescent, (Suppl. 97) S-115  
hepatic, (Suppl. 95) S-25  
myeloperoxidase, (Suppl. 95) S-25  
necrotising vasculitis, (Suppl. 97) S-115  
pauci-immune, (Suppl. 97) S-115  
proteinase-3, (Suppl. 95) S-25  
renal histology, (Suppl. 97) S-115  
vasculitis, (Suppl. 95) S-25
- Antiphospholipid syndrome**  
interleukin-35, 562  
pregnancy morbidity, 562  
thrombosis, 562
- Atherosclerosis**  
Sjögren's syndrome, 133
- Autoimmune diseases**  
autologous hematopoietic stem cells transept (ASCT), (Suppl. 98) S-53  
stem cell transplantation, (Suppl. 98) S-53
- Autoimmune thyroid disease**  
chronic lymphocytic thyroiditis, 296  
Hashimoto thyroiditis, 296  
spinal degenerative disc disease, 296  
spinal osteoarthritis, 296
- Autoinflammatory conditions**  
autophagy, (Suppl. 98) S-12  
biologics, 353  
childhood rheumatic diseases, (Suppl. 101) S-11  
familial Mediterranean fever, (Suppl. 102) S-129  
juvenile, (Suppl. 102) S-129  
health questionnaire, (Suppl. 101) S-11  
mitochondria, (Suppl. 98) S-12  
mitophagy, (Suppl. 98) S-12  
mtDNA, (Suppl. 98) S-12  
mtROS, (Suppl. 98) S-12  
multidimensional, (Suppl. 102) S-129  
NLRP3 inflammasome, (Suppl. 98) S-12  
outcome instrument, (Suppl. 102) S-129  
patient reported outcomes, (Suppl. 101) S-11  
PFAPA syndrome, (Suppl. 102) S-77  
proxy report, (Suppl. 102) S-129  
Schnitzler's syndrome, 353
- Behçet's disease**  
allergic diseases, (Suppl. 102) S-111  
anticoagulation, (Suppl. 95) S-3  
aortic regurgitation, (Suppl. 102) S-26  
Beliefs about Medicines Questionnaire (BMQ), (Suppl. 102) S-46  
beta2 integrin, (Suppl. 102) S-86  
biologic therapy, (Suppl. 102) S-34  
bronchial arteries, (Suppl. 102) S-92  
causal analysis, (Suppl. 102) S-101  
CD11a, (Suppl. 102) S-86  
CD11c, (Suppl. 102) S-86  
CD11c+CD8+ T cells, (Suppl. 102) S-86  
cholesterol, (Suppl. 102) S-136  
colchicine, (Suppl. 102) S-136  
disease management, (Suppl. 102) S-10  
Ets-1, (Suppl. 102) S-56  
gene-set enrichment, (Suppl. 102) S-101  
genetic, (Suppl. 102) S-41  
haemoptysis, (Suppl. 102) S-92  
immunosuppressive agents, (Suppl. 102) S-26  
immunosuppressive treatment, (Suppl. 95) S-3  
lipid, (Suppl. 102) S-136  
lumping, (Suppl. 102) S-23  
medication beliefs, (Suppl. 102) S-46  
meta-analysis, (Suppl. 102) S-41  
microRNA-155, (Suppl. 102) S-56  
Necessity Concerns Framework, (Suppl. 102) S-46  
neuro-Behçet's syndrome, (Suppl. 102) S-82  
outcome assessment, (Suppl. 102) S-10  
paravalvular leakage, (Suppl. 102) S-26  
pathogenesis, (Suppl. 102) S-10  
posterior uveitis, (Suppl. 102) S-82  
PTPN22, (Suppl. 102) S-41  
pulmonary artery, (Suppl. 102) S-92  
R620W, (Suppl. 102) S-41  
Silk Road disease, (Suppl. 102) S-111  
splitting, (Suppl. 102) S-23  
text mining, (Suppl. 102) S-101  
Th1, (Suppl. 102) S-111  
Th17 cells, (Suppl. 102) S-56  
Th2, (Suppl. 102) S-111  
therapeutic embolisation, (Suppl. 102) S-92  
therapeutics, (Suppl. 102) S-10  
Turkish translation reliability and validity, (Suppl. 102) S-46  
uveitis, (Suppl. 102) S-34  
venous thrombosis, (Suppl. 95) S-3  
wisdom versus knowledge, (Suppl. 102) S-23
- Behçet's syndrome (see Behçet's disease)**  
Bile acid signaling  
adaptive and innate immunity, (Suppl. 98) S-25  
cholangiopathies, (Suppl. 98) S-25  
G protein coupled receptors, (Suppl. 98) S-25  
hepatitis, (Suppl. 98) S-25  
nuclear hormone receptors, (Suppl. 98) S-25
- Biologics**  
anakinra, 531  
autoinflammatory diseases, 353  
etanar, 954  
etanercept, 954  
Schnitzler's syndrome, 353
- Bisphosphonate treatment**  
diabetes mellitus, (Suppl. 95) S-24  
sarcopenia, (Suppl. 95) S-24
- B-lymphocytes**  
infection, (Suppl. 98) S-1  
interleukin, (Suppl. 98) S-1  
interleukin-10, (Suppl. 98) S-1  
interleukin-35, (Suppl. 98) S-1  
Listeria, (Suppl. 98) S-1  
Salmonella, (Suppl. 98) S-1
- Calcium pyrophosphate dihydrate deposition disease (CPPD)**  
ageing, (Suppl. 98) S-32  
ankylosis human gene (ANKH), (Suppl. 98) S-32  
osteoarthritis, (Suppl. 98) S-32  
sensitivity and specificity, 254  
synovial fluid, 254  
ultrasound, 254  
x-rays, 254

- Cells (A11)  
Cells (A11), (Suppl. 98) S-6
- Chondrocalcinosis  
sensitivity and specificity, 254  
synovial fluid, 254  
ultrasound, 254  
x-rays, 254
- Congenital heart block  
anti-SSA/Ro antibodies, 706  
anti-SSB/La antibodies, 706  
intravenous immunoglobulins, 706  
plasmapheresis, 706
- Connective tissue diseases  
adipokines, 1101  
adiponectin, 1101  
chemerin, 1101  
diagnostic accuracy, 11  
interstitial lung disease, 11  
leptin, 1101  
lung ultrasound, 11  
meta-analysis, 11  
Moyamoya disease, (Suppl. 100) S-210  
resistin, 1101  
systemic sclerosis, (Suppl. 100) S-210  
systemic vasculitis, (Suppl. 97) S-60  
visfatin, 1101
- Corrona registry  
biological agents, (Suppl. 101) S-96  
cost effectiveness, (Suppl. 101) S-96  
rheumatoid arthritis, (Suppl. 101) S-96
- Cryopyrin-associated periodic syndromes (CAPS)  
anti interleukin-1, (Suppl. 102) S-115  
children, (Suppl. 102) S-115  
macrophage activation syndrome (MAS), (Suppl. 102) S-115  
mosaicism, (Suppl. 102) S-115
- Cutaneous vasculitis  
bacterial infection, (Suppl. 97) S-93  
histopathology, (Suppl. 97) S-93  
skin biopsy, (Suppl. 97) S-93
- DANBIO registry  
rheumatoid arthritis, (Suppl. 101) S-75
- Early arthritis  
anti-nuclear antibodies, 207  
parvovirus, 207  
polyarthritis, 207  
serology, 207
- Early psoriatic arthritis  
enthesitis, 459  
ultrasound, 459
- Early rheumatoid arthritis  
enthesitis, 459  
ultrasound, 459
- Economics  
rheumatoid arthritis, 1033  
Turkey, 1033
- Electronic medical record  
axial spondyloarthritis, (Suppl. 101) S-57  
e-health, (Suppl. 101) S-2  
economic assessment, (Suppl. 101) S-54  
electronic health record, (Suppl. 101) S-62  
health Apps, (Suppl. 101) S-54  
health services research, (Suppl. 101) S-62  
mobile Apps, (Suppl. 101) S-2  
patient m-reported outcomes, (Suppl. 101) S-2, S-54, S-62  
questionnaire, (Suppl. 101) S-5  
RADAI-5, (Suppl. 101) S-5  
rheumatoid arthritis, (Suppl. 101) S-2, S-5, S-17, S-49  
systemic lupus erythematosus, (Suppl. 101) S-54
- Familial Mediterranean fever  
amyloidosis, (Suppl. 102) S-72, S-138  
Armenia, (Suppl. 102) S-72  
B regulatory cells, (Suppl. 102) S-52  
carrier rate, (Suppl. 102) S-97  
cholesterol, (Suppl. 102) S-136  
colchicine, (Suppl. 102) S-136  
hyperaemic lesions, (Suppl. 102) S-138  
inflammation, (Suppl. 102) S-52  
lipid, (Suppl. 102) S-136  
MEFV gene, (Suppl. 102) S-72  
MEFV mutational, (Suppl. 102) S-97  
psoriasis, (Suppl. 102) S-137  
SAA gene, (Suppl. 102) S-72  
semaphorin 3A, (Suppl. 102) S-52  
T regulatory cells, (Suppl. 102) S-52  
Turkish population, (Suppl. 102) S-97
- Fatigue  
multidimensional model, 200  
rheumatoid arthritis, 200  
treatment, 200
- FDG-PET/CT  
autoimmune pancreatitis, 119  
diagnosis, 119  
IgG4-related disease, 119  
standardised uptake value, 119
- Fibromyalgia  
2010 ACR Preliminary Diagnostic Criteria for Fibromyalgia, (Suppl. 96) S-55  
active transportation, (Suppl. 96) S-67  
activity impairment, (Suppl. 96) S-106  
algometry, (Suppl. 96) S-14  
antidepressant, (Suppl. 96) S-106  
anxiety, (Suppl. 96) S-140  
assessment, (Suppl. 96) S-145  
burden, (Suppl. 96) S-106  
child abuse, (Suppl. 96) S-59  
child adversity, (Suppl. 96) S-59  
chronic pain, (Suppl. 96) S-3, S-34, S-48, S-55, S-67, S-125  
clinical assessment, (Suppl. 96) S-14  
cognitive dysfunctions, (Suppl. 96) S-6  
cognitive symptoms, (Suppl. 96) S-48  
combination therapy, (Suppl. 96) S-152  
concomitant fibromyalgia, (Suppl. 96) S-120  
core symptoms, (Suppl. 96) S-14  
cost of illness, (Suppl. 96) S-74  
database, (Suppl. 101) S-100  
demography, (Suppl. 96) S-134  
depression, (Suppl. 96) S-9, S-40, S-140  
diagnostic signature, (Suppl. 96) S-89  
disability, (Suppl. 96) S-99  
disease activity, 901, (Suppl. 96) S-40  
dyscognition, (Suppl. 96) S-6, S-48  
endogenous pain modulatory system, (Suppl. 96) S-129  
etiopathogenesis, (Suppl. 96) S-145  
fatigue, 901  
fibro-fog, (Suppl. 96) S-6  
gene expression, (Suppl. 96) S-89  
health care costs, (Suppl. 96) S-74  
health status, (Suppl. 96) S-134  
healthcare resource utilisation, (Suppl. 96) S-106  
highly active antiretroviral therapy (HAART), (Suppl. 96) S-34  
HIV, (Suppl. 96) S-34  
illness perceptions, (Suppl. 96) S-74  
lung, (Suppl. 96) S-114  
magnetic resonance imaging (MRI), (Suppl. 96) S-129  
major depression, (Suppl. 96) S-150  
men, (Suppl. 96) S-26
- mental disorders, (Suppl. 96) S-140  
monocytes, (Suppl. 96) S-150  
obesity, (Suppl. 96) S-83  
osteoarthritis, (Suppl. 96) S-55, S-125  
outcome, 521  
pain, (Suppl. 96) S-59, S-99, S-120, S-134, S-140, S-152  
pain sensitivity, (Suppl. 96) S-59  
panic disorder, (Suppl. 96) S-99  
paracetamol, (Suppl. 96) S-152  
patient-reported outcome, 901  
pathophysiology, (Suppl. 96) S-89  
pentraxin 3, (Suppl. 96) S-150  
periaqueductal grey (PAG), (Suppl. 96) S-129  
pharmaco-epidemiology, (Suppl. 101) S-100  
phenotype, (Suppl. 96) S-89  
PTX-3, (Suppl. 96) S-151  
reference standard, (Suppl. 96) S-14  
research criteria, (Suppl. 96) S-26  
rheumatic disorders, (Suppl. 96) S-120  
rheumatoid arthritis, (Suppl. 96) S-55, S-125  
Sjögren's syndrome, (Suppl. 96) S-9  
social-economic factors, (Suppl. 96) S-67  
socioeconomic status, (Suppl. 96) S-83  
stress, (Suppl. 96) S-140  
symptom profile, (Suppl. 96) S-26, S-59  
systemic lupus erythematosus, (Suppl. 96) S-40  
therapies, (Suppl. 96) S-145  
tramadol, (Suppl. 96) S-152  
treatment, 521  
vitamin D, (Suppl. 96) S-9  
women, (Suppl. 96) S-26  
work productivity, (Suppl. 96) S-106
- Giant cell arteritis  
age, (Suppl. 97) S-70  
biopsy, (Suppl. 97) S-40  
colour duplex sonography, (Suppl. 97) S-70  
disease pattern, (Suppl. 97) S-70  
gender, (Suppl. 97) S-70  
gene deletion, (Suppl. 100) S-208  
histopathology, (Suppl. 97) S-40LILRA3, (Suppl. 100) S-208
- Glucocorticoids  
damage, 466  
hydroxychloroquine, 466  
immunosuppressive drugs, 466  
lupus activity, 466  
lupus nephritis, 466
- Gout  
treatment, (Suppl. 98) S-63
- Granulomatosis with polyangiitis  
neutrophil activation, (Suppl. 97) S-98  
neutrophil extracellular traps, (Suppl. 97) S-98  
neutrophil-platelets aggregates, (Suppl. 97) S-98  
serum nucleases activity, (Suppl. 97) S-98
- Henoch-Schönlein purpura  
IL1 $\beta$ , (Suppl. 97) S-84  
rs16944, (Suppl. 97) S-84  
vasculitis, (Suppl. 97) S-84
- Hypersensitivity reactions  
allergy, 129  
biological agents, 129  
IgE, 129
- IgA vasculitis  
adults, (Suppl. 97) S-77

- age, (Suppl. 97) S-77  
 outcome, (Suppl. 97) S-77
- IgG4-related disease  
 cranial base IgG4, 1126  
 cytotoxic T cell, (Suppl. 98) S-66  
 FDG-PET/CT, 119  
 IgG4 hypophysitis, 1126  
 IgG4 pachymeningitis, 1126  
 plasmablast, (Suppl. 98) S-66  
 skull base IgG4-related disease, 1126  
 SLAMF7, (Suppl. 98) S-66
- Immune system  
 Immune system (A15), (Suppl. 98) S-6  
 Immune system diseases (C20), (Suppl. 98) S-6
- Inflammation  
 cardiovascular risk, 451  
 coagulation, 451  
 prothrombotic biomarkers, 451
- Inflammatory bowel disease (IBD)  
 anti-rheumatic agents, 698  
 biosimilar pharmaceuticals, 698  
 CT-P13, 698  
 spondyloarthritis, 1085  
 therapeutic equivalence, 698
- Inflammatory myopathies  
 anti-Jo-1, 222  
 BAFF, 222  
 causes of death, 820  
 circulating microRNA, 17  
 computed tomography, 723  
 dermatomyositis, 723  
 esophagitis, 723  
 extramuscular complications, 820  
 immunosuppressant, 880  
 intravenous immunoglobulins, 720  
 long-term survival, 820  
 magnetic resonance imaging (MRI), 1098  
 methotrexate, 720  
 muscle disease, 880  
 muscle enzymes, 222  
 myalgia, 918  
 mycophenolate mofetil, 720, 723  
 myositis dot-blot assay, 918  
 nuclear medicine, 723  
 pathogenesis, 966  
 poly-dermatomyositis, 723, 1098  
 positron emission tomography (PET), 723  
 predictors of poor prognosis, 820  
 rituximab, 720  
 serum, 17  
 treatment, 880, 966  
 visfatin, 222
- Information technology systems, Suppl. 101  
 management, (Suppl. 101) S-73  
 psoriatic arthritis, (Suppl. 101) S-73  
 treat to target, (Suppl. 101) S-73  
 treatment, (Suppl. 101) S-73
- Juvenile ankylosing spondylitis  
 modified Stoke AS Spinal Score, 668
- Juvenile idiopathic arthritis  
 adverse effects, 148  
 child, 941  
 cross-sectional study, 548  
 environmental, 946  
 exclusive enteral nutrition, 941  
 FHL, 719  
 inflammation, 337  
 joints, 941  
 lymphoma, 1113  
 macrophage activation syndrome, 719  
 malignancy, 1113  
 methotrexate, 148, 548, 714, 1113  
 monitoring serum etanercept levels, 955  
 musculoskeletal, 957  
 particulate matter, 946  
 perforin gene, 719  
 pollution, 946  
 pro-inflammatory cytokines, 337  
 questionnaire, 548  
 regulatory cytokines, 337  
 route of administration, 148  
 spondyloarthritis, 719  
 subclinical, 143  
 subcutaneous injections, 148  
 survey, 957  
 synovitis, 337  
 toxicity, 548  
 tumour-necrosis-factor  $\alpha$  inhibitors, 1113  
 ultrasound, 1, 143, 957  
 uveitis, 714
- Juvenile spondyloarthropathies  
 ultrasound, 143
- Juvenile-onset scleroderma  
 eosinophilia, 527  
 paediatrics, 527  
 rheumatology, 527
- Kawasaki disease  
 coronary aneurism, (Suppl. 97) S-139  
 immunoglobulin, (Suppl. 97) S-139  
 incidence, (Suppl. 97) S-139  
 India, (Suppl. 97) S-129, S-134  
 infliximab, (Suppl. 97) S-134  
 mortality, (Suppl. 97) S-129
- Macrophage activation syndrome  
 spondyloarthritis, 953
- Magnetic resonance imaging (MRI)  
 hand osteoarthritis, 991  
 myositis, 1098  
 poly-dermatomyositis, 1098
- Methotrexate  
 recommendations, 473  
 rheumatoid arthritis, 473
- Mixed connective tissue disease  
 anti-synthetase syndrome, (Suppl. 100) S-181  
 bosentan, 1125  
 lung involvement, (Suppl. 100) S-181  
 Ortner's syndrome, 1125  
 pulmonary arterial hypertension, 1125  
 rituximab, (Suppl. 100) S-181  
 systemic sclerosis, (Suppl. 100) S-181  
 therapy, (Suppl. 100) S-181
- Mixed cryoglobulinemia  
 B-cell, (Suppl. 97) S-28  
 hepatitis B virus, (Suppl. 97) S-28  
 hepatitis C virus, (Suppl. 97) S-28  
 natural antibodies, (Suppl. 97) S-28  
 VH1-69, (Suppl. 97) S-28
- Monckeberg's sclerosis  
 atherosclerosis, 354  
 calcification, 354  
 SAPHO, 354
- Moyamoya disease  
 connective tissue disease, (Suppl. 100) S-210  
 systemic sclerosis, (Suppl. 100) S-210
- Mud-bath therapy  
 knee osteoarthritis, 618
- Non-pharmacotherapy  
 guidelines, (Suppl. 95) S-15  
 implementation, (Suppl. 95) S-15  
 recommendations, (Suppl. 95) S-15  
 review, (Suppl. 95) S-15
- Ortner's syndrome  
 bosentan, 1125  
 mixed connective tissue disease, 1125  
 pulmonary arterial hypertension, 1125
- Osteoarthritis  
 ageing, (Suppl. 98) S-32  
 ankylosis human gene (ANKH), (Suppl. 98) S-32  
 articular cartilage, 929  
 autoantibodies, 513  
 calcium pyrophosphate crystal deposition (CPPD), (Suppl. 98) S-32  
 chronic pain, (Suppl. 96) S-125  
 database, (Suppl. 101) S-100  
 differentially expressed genes, 282  
 disease activity, 901  
 fatigue, 901  
 fibromyalgia, (Suppl. 96) S-125  
 hand, biologic markers, 991  
 hand, magnetic resonance imaging (MRI), 991  
 hand, radiology, 991  
 HYADD 4, 857  
 hyaluronic acid, 857  
 injection, 857  
 knee, 857  
 knee, fibroblast growth factor 18, 445  
 knee, glucosamine, 618  
 knee, mud-bath therapy, 618  
 knee, pressure algometry, 158  
 knee, pressure pain sensitivity, 158  
 knee, reliability, 158  
 knee, sprifermin, 445  
 pain, 929  
 pathway cross-talk, 282  
 patient reported outcomes, 901  
 perturbation analysis, 282  
 pharmaco-epidemiology, (Suppl. 101) S-100  
 protein-protein interaction, 282  
 rheumatoid arthritis, 513  
 subchondral bone, 929  
 ultrasound, 1
- Osteoporosis  
 observational study, 247  
 spinal fractures, 247  
 teriparatide, 247  
 therapy, 247
- P value  
 ill use, (Suppl. 95) S-8  
 post-modern, (Suppl. 95) S-8
- Paediatric rheumatology  
 autoinflammatory diseases, (Suppl. 101) S-11  
 childhood rheumatic diseases, (Suppl. 101) S-11  
 health questionnaires, (Suppl. 101) S-11  
 patient-reported outcomes, (Suppl. 101) S-11
- Patient-reported outcomes  
 disease activity, 901  
 fatigue, 901  
 fibromyalgia, 901  
 osteoarthritis, 901  
 rheumatoid arthritis, 901  
 systemic lupus erythematosus, 901
- PFAPA syndrome  
 autoinflammation, (Suppl. 102) S-77  
 prednisone, (Suppl. 102) S-77  
 tonsillectomy, (Suppl. 102) S-77
- Pregnancy  
 rheumatic disease, 172  
 biologic agents, 172

- congenital malformations, 172  
disease-modifying anti-rheumatic drugs, 172
- Psoriasis  
bone loss, (Suppl. 98) S-17  
familial Mediterranean fever, (Suppl. 102) S-137  
IL-17A, (Suppl. 98) S-17  
osteoblast, (Suppl. 98) S-17  
psoriatic arthritis, 276  
skin inflammation, (Suppl. 98) S-17  
spondyloarthritis, 82
- Psoriatic arthritis, (Suppl. 98) S-69  
adjuvant, 507  
anti-TNF- $\alpha$  therapy, 507  
anti-tumour necrosis factor agents, 68  
biologic failure, (Suppl. 95) S-12  
biologic therapy, 1051, (Suppl. 98) S-9  
biological DMARD, (Suppl. 98) S-49  
cardiovascular risk, 276  
costs, 68  
cytokine, (Suppl. 98) S-49  
diabetes, 276  
diagnosis, 1051  
disease activity, 507  
DMARDs, 1051  
enthesitis, 1020  
etanercept, 1094  
influenza vaccination, 507  
information technology, (Suppl. 101) S-73  
pathogenesis, (Suppl. 98) S-9  
polyarthritis, 276  
primary care, 1020  
psoriasis, 276, 1020  
quality of life, 68  
receptors tumour necrosis factor/therapeutic use, 1059  
remission, 1094  
strategy, (Suppl. 98) S-9  
tacrolimus, (Suppl. 95) S-12  
therapy, 1051  
treatment, (Suppl. 98) S-49  
treatment outcome, 1059  
ultrasonography, 1, 1020
- Pulmonary arterial hypertension  
mixed connective tissue disease, 1125  
Ortner's syndrome, 1125
- Raynaud disease  
adolescent, (Suppl. 100) S-200  
autoantibodies, (Suppl. 100) S-200  
child, (Suppl. 100) S-200  
microscopic angiopathy, (Suppl. 100) S-200
- Recessive dystrophic epidermolysis bullosa  
inflammation, 961  
interleukin (IL)-1 $\beta$ , 961  
therapy, 961
- Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE)  
tenosynovitis, 404
- Rheumatoid arthritis  
abatacept, 37, 489, 834, 1122  
activity, 827  
adherence, 694  
ankle, 480  
ankylosis, 49  
anti-CCP, 424  
anti-citrullinated protein antibodies (ACPA), 236  
anti-RA33 antibody, 539  
anti-rheumatic agents, 261, 698, 1065  
anti-TNF, 329, 357  
Asian, 157  
atherosclerosis, 58, 864  
atlantoaxial spinal fusion, 1045  
atlantoaxial subluxation, 1045  
autoantibodies, 513, (Suppl. 100) S-49  
autoimmunity, (Suppl. 98) S-45  
automated assessment, (Suppl. 101) S-34  
B lymphocytes, 793  
biologic agents, 872, 1026, 1065, (Suppl. 101) S-79, S-96  
biologic drugs, 625, 694, 893  
biomarker, 539  
biosimilars, 698, (Suppl. 95) S-9  
blindness, (Suppl. 95) S-18  
bone, 49  
bone erosions, 673  
bone marrow, 329  
CAMERA, (Suppl. 101) S-69  
cardiac magnetic resonance, 416  
cardiovascular disease, 58, 106, 416, 813  
cardiovascular risk, 230, 793  
carotid intima-media thickness, 230, 1013  
carotid plaques, 1013  
caspase-1 inhibitor, 111  
cathepsin S, 230  
CD28 superagonist, (Suppl. 98) S-45  
CD4 positive T-lymphocyte, 685  
chronic pain, (Suppl. 96) S-125  
claims data, (Suppl. 101) S-79  
Clinical Disease Activity Index (CDAI), 808  
Clinical Disease Activity Index (CDAI)/Simplified Disease Activity Index (SDAI), (Suppl. 101) S-45  
clinical outcome, 655  
clinical remission, 673  
clinical trial, 88  
cohort studies, 489, 813  
comorbidity, 261, 813  
complication, 270, 1045  
comprehensive disease remission, 834  
computer decision software, (Suppl. 101) S-69  
computerised, (Suppl. 101) S-34  
Corrona registry, (Suppl. 101) S-96  
cost, 679  
cost effectiveness, (Suppl. 101) S-96  
CTLA-4 Ig, 315, 500  
CT-P13, 698  
cyclic citrullinated peptide, 489  
cystatin C, 230  
cytokine peptide, 242  
cytokines, 318  
DANBIO registry, (Suppl. 101) S-75  
disease activity index-28 (DAS28), 424, 999, (Suppl. 101) S-40, S-69  
database, (Suppl. 101) S-100  
deep clinical remission, 581  
deficiency, 827  
depression, (Suppl. 100) S-49  
dexamethasone, 500  
diagnostic value, 539  
disease activity, 157, 303, 646, 802, 901, 984, (Suppl. 101) S-45, S-69  
disease-modifying anti-rheumatic drugs (DMARDs), 357, 893  
dormant bacteria, 329  
dose escalation, 679  
early arthritis, 58  
echocardiography, 352  
economic burden of disease, 1033  
e-health, (Suppl. 101) S-2  
electronic assessment tools, (Suppl. 101) S-2, S-5  
electronic medical record (EMR), (Suppl. 101) S-17, S-49  
endocrinology, 848  
endothelial activation, 864  
epidemiology, 303  
EQ-5D, 999  
ESPOIR cohort, 646  
Europe, 679  
fatigue, 200, 848, 901  
fibromyalgia, (Suppl. 96) S-55, S-125  
foot, 480  
gait, 561  
gene expression, 106, 685  
genetic association studies, 236  
genetics, 793  
glucocorticoids, 303, 685, 1038  
GM-CSF, (Suppl. 98) S-39  
granzyme, 37  
HAQ, 999  
healthcare cost, 1033  
high resolution computed tomography, 564  
IL-6, 451  
immune response, 318, 848  
immunosuppression, (Suppl. 95) S-18  
infection, 261  
information technology, (Suppl. 101) S-17, S-45, S-49  
interactive electronic platform, (Suppl. 101) S-75  
interleukin, 848  
interleukin 1 receptor antagonist protein, 88  
interstitial lung disease, 564, 587  
intra-articular injections, 1038  
ischemic heart disease, 106  
Janus kinase, 318, 430  
joint space width, (Suppl. 101) S-34  
Larsen score, 641  
late gadolinium enhancement, 416  
left ventricular diastolic dysfunction, 352  
lipids, 1013  
longitudinal studies, 813  
macrophages, 500  
magnetic resonance imaging (MRI), 49  
mavrilimumab, (Suppl. 98) S-39  
membranous nephropathy, 1122  
mesenchymal, 329  
meta-analysis, 539  
methotrexate, 473, 500, 694  
methylene tetrahydrofolate reductase (MTHFR), 106  
mobile Apps, (Suppl. 101) S-2  
MOR103, (Suppl. 98) S-39  
mortality, 813, 1026, 1045, (Suppl. 95) S-18  
multidimensional health assessment questionnaire (MDHAQ), (Suppl. 101) S-17, S-49  
multidimensional model, 200  
namilumab, (Suppl. 98) S-39  
Nationwide Inpatient Sample, 270, 1045  
new therapies, 357  
niche, 329  
observational studies, 872, (Suppl. 101) S-79  
optimisation, 872  
osteoarthritis, 513  
pain, 430, (Suppl. 100) S-49  
panniculitis, 126  
patient-reported outcomes, 646, 901, (Suppl. 101) S-2  
PCSK9, 1013  
peripheral ulcerative keratitis, (Suppl. 95) S-18  
personalised medicine, (Suppl. 101) S-40

- pharmaco-epidemiology, (Suppl. 101) S-100  
 podiatry, 480  
 power Doppler, 673  
 power Doppler and grey-scale US, 156  
 predictions and projections, 1065  
 predictor, 156  
 prevalence, 984  
 pro-inflammatory cytokines, 111  
 protocol compliance, 1038  
 quality of care, (Suppl. 101) S-87  
 quality of life, 430, 999, 1038  
 questionnaire, (Suppl. 101) S-5  
 RA outcomes, 641  
 RADAI-5, (Suppl. 101) S-5  
 radiographic damage, 641  
 radiography, 625, 1065  
 recommendations, 473  
 registers, (Suppl. 101) S-79  
 registry, (Suppl. 101) S-87  
 regulatory T-cells, (Suppl. 98) S-45  
 relapse, 581  
 remission, (Suppl. 101) S-69  
 response to TNF inhibitor, 156  
 rheumatoid factor, 489  
 rheumatoid factor IgA, IgG, IgM, 424  
 right and left ventricle, 352  
 rituximab, 424, 893  
 routine assessment of patient index data (RAPID3), (Suppl. 101) S-17, S-49  
 safety, 893  
 secular trends, (Suppl. 101) S-45  
 self-monitoring, (Suppl. 101) S-40  
 Sharp/van der Heijde score, (Suppl. 101) S-34  
 sleep, 848 (Suppl. 100) S-49  
 SNP, 236  
 soluble TNF- $\alpha$ , 242  
 stem cells, 329  
 structural remission, 834  
 subclinical synovitis, 581  
 surgery, 1045  
 survey, 694, (Suppl. 95) S-9  
 synovial biopsy, 802  
 synovitis, 157, 673  
 synovium, 1072  
 systemic lupus erythematosus, 1122  
 T cells, 37  
 T lymphocytes, 793  
 T1 mapping, 416  
 TAB08, (Suppl. 98) S-45  
 tapering strategy, 655  
 telomere length, 864  
 temporomandibular joint, 561  
 TGN1412, (Suppl. 98) S-45  
 the van der Heijde-modified total Sharp score, 834  
 therapeutic equivalence, 698  
 thrombin, 925  
 thrombosis, 925  
 tight control, (Suppl. 101) S-69  
 tissue Doppler imaging, 352  
 TNF inhibitors, 655, 679, 999  
 TNF $\alpha$  therapeutic immunisation, 242  
 tocilizumab, 303, 451, 808  
 tofacitinib, 318, 430  
 total hip arthroplasty, 270  
 total knee arthroplasty, 270  
 treatment, 200, 357, 655  
 treatment efficacy, 32  
 treatment with etanercept versus methotrexate, 848  
 treat-to-target, 808, (Suppl. 101) S-69  
 tumour marker, 587  
 tumour necrosis factor inhibitors, 1072  
 Turkey, 1033  
 type 1 diabetes mellitus, 315  
 ultrasonographic disease activity, 156  
 ultrasonographic remission, 581  
 ultrasonography, 1, 480, 157, 561, 673, 802, 1072  
 undifferentiated arthritis, 58  
 United States, 32  
 usual interstitial pneumonia, 564  
 virus, 329  
 vitamin D, 827  
 vitamin D deficiency, 984  
 VX765, 111  
 wrist, 49  
 Rheumatoid factor  
 IgA, 424  
 IgG, 424  
 IgM, 424  
 Rheumatology Informatics System for Effectiveness (RISE) registry  
 clinical quality improvement, (Suppl. 101) S-102  
 chronic disease registry, (Suppl. 101) S-102  
 SAPHO  
 atherosclerosis, 354  
 calcification, 354  
 Monckeberg's sclerosis, 354  
 Sarcoidosis  
 epidemiology, 380  
 ethnicity, 380  
 Schnitzler's syndrome  
 autoinflammatory diseases, 353  
 biologics, 353  
 infections, 353  
 therapy, 353  
 Sjögren's syndrome  
 atherosclerosis, 133, 1006  
 autoantibodies, 25, 722  
 BAFF, 1123  
 B cells, 25, 311  
 belimumab, 311  
 biologics, (Suppl. 98) S-58  
 biomarkers, 133, 161, 1006  
 calprotectin, 1006  
 chemiluminescence, 722  
 chemokines, (Suppl. 98) S-58  
 child, 343  
 cytokines, 959, (Suppl. 98) S-58  
 depression, (Suppl. 96) S-9  
 diagnosis in children, 343  
 endostatin, 690  
 EQ-5D-5L, 663  
 ESSPRI, 560, 663  
 fatigue, 373  
 fibromyalgia, (Suppl. 96) S-9  
 focal lymphocytic sialadenitis, 1123  
 interstitial lung disease, 1077  
 invariant NKT cells, 25  
 isoform, 959  
 lymphoma, 161  
 minor salivary gland biopsy, 1123  
 paediatrics, 343  
 parotitis, 343  
 pathogenesis, 161, 690  
 patient outcome assessment, 663  
 patient-reported outcome, 560  
 physical activity, 560  
 Pittsburgh Sleep Quality Index, 373  
 primary, 560, (Suppl. 98) S-58  
 quality of life, 663  
 rheumatoid factor, 311, 722  
 risk factors, 133, 1006  
 rituximab, 311, 1077, 1123  
 salivary gland, 959  
 sleep disorders, 373  
 SSA/SSB, 722  
 stromal cells, (Suppl. 98) S-58  
 subclinical cardiovascular disease, 133, 1006  
 thymic stromal lymphopoietin, 959  
 TLOs, (Suppl. 98) S-58  
 ultrasonography, 161  
 vitamin D, (Suppl. 96) S-9  
 Skin disease  
 inflammation, 961  
 interleukin (IL)-1 $\beta$ , 961  
 recessive dystrophic epidermolysis bullosa, 961  
 therapy, 961  
 Sleep disorders  
 Sjögren's syndrome, 373  
 Spondyloarthritis  
 ankylosing spondylitis, (Suppl. 95) S-7  
 anti-TNF agents, 329, 935  
 ASAS, (Suppl. 95) S-7  
 assessment, 963, 1121  
 bone marrow, 329  
 burden, 963, 1121  
 cardiovascular disease, 159  
 carotid ultrasound, 159  
 classification, 963, 1121, (Suppl. 95) S-5, S-7  
 comorbidities, 396  
 cost per responder, 935  
 criteria, 963, 1121  
 dactylitis, 842  
 DESIR Cohort, 396  
 diagnosis, (Suppl. 95) S-5  
 disease activity, 396, (Suppl. 101) S-57  
 disease expression, 575  
 dormant bacteria, 329  
 electronic assessment, (Suppl. 101) S-57  
 enteropathic arthritis, 842  
 enthesitis, 721  
 familial forms, 575  
 FHL, 719  
 haemophagocytic lymphohistiocytosis, 953  
 inflammatory bowel disease, 842, 1085  
 innate lymphoid cells, 1085  
 interleukin-17, 1085  
 juvenile idiopathic arthritis, 719  
 macrophage activation syndrome, 719, 953  
 magnetic resonance imaging (MRI), (Suppl. 95) S-5  
 mesenchymal, 329  
 mutation, 953  
 niche, 329  
 non-radiographic, 963, 1121, (Suppl. 95) S-7  
 number needed to treat, 935  
 perforine gene, 719  
 psoriasis, 82  
 spondyloarthritis, 725  
 sporadic, 575  
 stem cells, 329  
 subclinical atherosclerosis, 159  
 ultrasound, 1, 721, 721  
 uveitis, 953  
 virus, 329  
 vitamin D, 396  
 Stem cell transplantation  
 autoimmune diseases, (Suppl. 98) S-53  
 autologous hematopoietic stem cells  
 transept (ASCT), (Suppl. 98) S-53  
 immune reconstitution, (Suppl. 98) S-53  
 immune reset, (Suppl. 98) S-53

- Systemic autoinflammatory disorders  
 gene expression profiling, (Suppl. 102) S-121  
 gene pathways, (Suppl. 102) S-121  
 TNF receptor-associated periodic syndrome, (Suppl. 102) S-121  
 TNFRSF1A gene, (Suppl. 102) S-121
- Systemic lupus erythematosus  
 abatacept, 1122  
 anxiety, 389  
 arterial stiffness, 53  
 atherosclerosis, 42, 600  
 atorvastatin, 42  
 attribution models, 910  
 autoimmune, (Suppl. 98) S-21  
 belimumab, 355  
 biomarkers, 569  
 biomechanics, 609  
 cardiovascular diseases, 53  
 childhood, 554  
 comorbidities, 569  
 depression, 389, (Suppl. 96) S-40  
 diagnosis, 910  
 disease activity, 76, 291, 554, 901, (Suppl. 96) S-40  
 economic, (Suppl. 101) S-54  
 electronic assessment tools, (Suppl. 101) S-54  
 FAS, 634  
 fatigue, 901  
 fibromyalgia, (Suppl. 96) S-40  
 folic acid, 76  
 foot, 609  
 haemodynamics, 291  
 health Apps, (Suppl. 101) S-54  
 homocysteine, 76  
 infection, 554  
 interferon, (Suppl. 98) S-21  
 lupus nephritis, 355  
 membranous nephropathy, 1122  
 meta-analysis, 634  
 mice, 600  
 mortality, 554  
 neuropsychiatric, 910  
 pathogenesis, 569  
 patient management, (Suppl. 101) S-54  
 patient-reported outcomes, 901, (Suppl. 101) S-54  
 podiatry, 609  
 polymorphism, 634  
 pristane, 600  
 psychiatric, 389  
 pulmonary artery hypertension, 291  
 pulse wave velocity, 53  
 quality of life, 291, 389  
 receptors, 42  
 renal damage, 53  
 rheumatoid arthritis, 1122  
 rituximab, 355  
 SLICC/ACR Damage Index (SDI), 53  
 toll-like receptors, 600  
 treatment, 466, 569, (Suppl. 98) S-21  
 tumour necrosis factor, 42  
 ultrasound, 609  
 vitamin B12, 76  
 work disability, 389
- Systemic sclerosis  
 24-hour pH monitoring, (Suppl. 100) S-115  
 acoustic radiation force impulse, (Suppl. 100) S-137  
 acute kidney injury (AKI), (Suppl. 100) S-106  
 adolescents, (Suppl. 100) S-193  
 angiostatin, (Suppl. 100) S-37  
 anti-synthetase syndrome, (Suppl. 100) S-181  
 assessment, (Suppl. 100) S-142  
 asymmetric dimethylarginine (ADMA), (Suppl. 100) S-129  
 autoantibody, (Suppl. 100) S-49  
 autoimmunity, (Suppl. 100) S-30, S-43  
 autologous haematopoietic stem cell transplantation, (Suppl. 100) S-207  
 azathioprine, (Suppl. 100) S-170  
 biological markers, (Suppl. 100) S-110, S-129  
 bleomycin, (Suppl. 100) S-14  
 body image dissatisfaction, (Suppl. 100) S-70, S-92  
 calcinosis cutis, (Suppl. 100) S-177  
 cardiac response, (Suppl. 100) S-152  
 CD2, (Suppl. 100) S-43  
 CD95+ B cells, (Suppl. 100) S-30  
 children, (Suppl. 100) S-193  
 connective tissue diseases, (Suppl. 100) S-210  
 depression, (Suppl. 100) S-49  
 dialysis, (Suppl. 100) S-122  
 diffuse cutaneous, (Suppl. 100) S-74, S-142  
 digital ulcers, (Suppl. 100) S-100, S-142  
 disability, (Suppl. 100) S-162  
 disease activity index, (Suppl. 100) S-186  
 dysmotility, (Suppl. 100) S-115  
 dysphagia, (Suppl. 100) S-63  
 elastography ultrasound, (Suppl. 100) S-137  
 endostatin, (Suppl. 100) S-37  
 endothelial cells, (Suppl. 100) S-85  
 epidemiology, (Suppl. 100) S-74  
 exercise, (Suppl. 100) S-152  
 extracorporeal shock wave therapy (ESWT), (Suppl. 100) S-177  
 fecal incontinence, (Suppl. 100) S-63  
 fibroblast, (Suppl. 100) S-14  
 fibrosis, (Suppl. 100) S-23, S-85, S-110  
 gastroesophageal reflux disease (GORD), (Suppl. 100) S-115  
 gastrointestinal, (Suppl. 100) S-115  
 gene deletion, (Suppl. 100) S-208  
 genetics, (Suppl. 100) S-43  
 hand involvement, (Suppl. 100) S-157  
 healing, (Suppl. 100) S-100  
 health-related quality of life, (Suppl. 100) S-79  
 insulin resistance, (Suppl. 100) S-85  
 interleukin-17, (Suppl. 100) S-14  
 interstitial lung disease, (Suppl. 100) S-170  
 isopentenyl pyrophosphate, (Suppl. 100) S-23  
 kidney, (Suppl. 100) S-106  
 laser Doppler imaging, (Suppl. 100) S-100  
 LILRA3, (Suppl. 100) S-208  
 limited cutaneous scleroderma, (Suppl. 100) S-74, S-142  
 lung involvement, (Suppl. 100) S-181  
 manometry, (Suppl. 100) S-63, S-115  
 memory B cells, (Suppl. 100) S-30  
 mice, (Suppl. 100) S-14  
 mixed connective tissue disease, (Suppl. 100) S-181  
 Moyamoya disease, (Suppl. 100) S-210  
 multiparametric flow cytometry, (Suppl. 100) S-30  
 mycophenolate mofetil, (Suppl. 100) S-170  
 normal patterns, (Suppl. 100) S-193  
 N-TproBNP, (Suppl. 100) S-122  
 occupational therapy, (Suppl. 100) S-157  
 outcome, (Suppl. 100) S-122  
 overlap syndrome, (Suppl. 100) S-74  
 pain, (Suppl. 100) S-49  
 participation, (Suppl. 100) S-56  
 pathogenesis, (Suppl. 100) S-3  
 physical function, (Suppl. 100) S-79  
 physiotherapy, (Suppl. 100) S-162  
 polymorphism, (Suppl. 100) S-43  
 pulmonary arterial hypertension, (Suppl. 100) S-129, S-152  
 pulmonary function, (Suppl. 100) S-152  
 quality of life, (Suppl. 100) S-63, S-70, S-162  
 race/ethnicity, (Suppl. 100) S-92  
 rehabilitation, (Suppl. 100) S-162  
 renal, (Suppl. 100) S-106  
 review, (Suppl. 100) S-3  
 rituximab, (Suppl. 100) S-148, S-181  
 scleroderma renal crisis, (Suppl. 100) S-122  
 scoring system, (Suppl. 100) S-142  
 screening, (Suppl. 100) S-129  
 sensitivity to change, (Suppl. 100) S-148  
 sex, (Suppl. 100) S-92  
 shear-wave elastography, (Suppl. 100) S-137  
 sleep, (Suppl. 100) S-49  
 stretching program, (Suppl. 100) S-157  
 stroke, (Suppl. 100) S-210  
 support groups, (Suppl. 100) S-56  
 Th17 cells, (Suppl. 100) S-14  
 thermography, (Suppl. 100) S-100  
 thrombin, 925  
 thrombosis, 925  
 treatment, (Suppl. 100) S-3, S-181  
 ulcers, (Suppl. 100) S-85  
 ultrasound inter-assessor agreement, (Suppl. 100) S-177  
 validity, (Suppl. 100) S-148, S-186  
 vascular diseases, (Suppl. 100) S-210  
 videocapillaroscopy, (Suppl. 100) S-193  
 virtual touch and imaging quantification, (Suppl. 100) S-137  
 work disability, (Suppl. 100) S-79  
 zoledronic acid, (Suppl. 100) S-23  
 $\gamma\delta$  T cells, (Suppl. 100) S-23
- Systemic vasculitis  
 connective tissue disease, (Suppl. 97) S-60  
 cytokeratin 15, (Suppl. 97) S-60  
 granulomatosis with polyangiitis, (Suppl. 97) S-7  
 lamin C, (Suppl. 97) S-60  
 NA 14 nuclear autoantigen, (Suppl. 97) S-60  
 polyarteritis nodosa, (Suppl. 97) S-7  
 posterior reversible encephalopathy syndrome, (Suppl. 97) S-7  
 Takayasu's arteritis, (Suppl. 97) S-7
- Takayasu's arteritis  
 activity, (Suppl. 97) S-73  
 anaemia, (Suppl. 97) S-16  
 biological markers, (Suppl. 97) S-21  
 biological therapy, (Suppl. 97) S-44  
 body mass index, (Suppl. 97) S-16  
 cardiovascular disease, (Suppl. 97) S-16  
 cytokines, (Suppl. 97) S-21  
 epidemiology, (Suppl. 97) S-33  
 IL-6, (Suppl. 97) S-21  
 immune system, (Suppl. 97) S-21  
 incidence, (Suppl. 97) S-33  
 large vessel vasculitis, (Suppl. 97) S-44  
 lymphocytes, (Suppl. 97) S-21  
 pathogenesis, (Suppl. 97) S-21  
 pentraxin-3, (Suppl. 97) S-73

- prevalence, (Suppl. 97) S-33  
 tocilizumab, (Suppl. 97) S-44  
 Turkey, (Suppl. 97) S-33
- Tissues (A10)  
 Tissues (A10), (Suppl. 98) S-6
- Tofacitinib  
 rheumatoid arthritis, 318
- Ultrasonography  
 children, 957  
 enthesitis, 721  
 juvenile idiopathic arthritis, 1, 143  
 juvenile spondyloarthropathies, 143  
 osteoarthritis, 1  
 psoriatic arthritis, 1, 1020  
 rheumatoid arthritis, 1, 1072  
 spondyloarthritis, 1, 721
- Uric acid  
 adolescent, (Suppl. 95) S-22  
 epidemiology, (Suppl. 95) S-22  
 hyperuricaemia, (Suppl. 95) S-22
- Vasculitis  
 anti-neutrophil cytoplasmic antibodies (ANCA), (Suppl. 97) S-1, S-121, S-145  
 ANCA-associated, (Suppl. 97) S-105  
 ANCA-positive vasculitis, (Suppl. 97) S-145  
 anti-myeloperoxidase antibodies, (Suppl. 97) S-145  
 aortic structural damage, (Suppl. 95) S-14  
 atherosclerosis, (Suppl. 95) S-14  
 azathioprine, (Suppl. 97) S-146  
 biological therapy, (Suppl. 97) S-44  
 C4A6 allotype, (Suppl. 97) S-12  
 complement C4, (Suppl. 97) S-12  
 cryobulinemic vasculitis complications, (Suppl. 97) S-12  
 cutaneous, (Suppl. 97) S-93  
 EGPA, (Suppl. 97) S-1  
 elderly, (Suppl. 95) S-20  
 employment, (Suppl. 97) S-111  
 end stage renal disease, (Suppl. 97) S-105  
 eosinophilic granulomatosis with polyangiitis, (Suppl. 97) S-121  
 eosinophilic myocarditis, (Suppl. 97) S-146  
 epidemiology, (Suppl. 97) S-89  
 giant cell arteritis, (Suppl. 95) S-1, S-14  
 granulomatosis with polyangiitis, (Suppl. 97) S-121  
 Henoch-Schönlein purpura, (Suppl. 97) S-84  
 immunisation, (Suppl. 95) S-20  
 histopathology, (Suppl. 97) S-105  
 IgA vasculitis, (Suppl. 97) S-77  
 IL1 $\beta$ , (Suppl. 97) S-84  
 immunisations, (Suppl. 95) S-21  
 large vessel, (Suppl. 97) S-44  
 MHC, (Suppl. 97) S-12  
 microscopic polyangiitis, (Suppl. 97) S-121, S-145  
 plasma exchange, (Suppl. 97) S-105  
 pulmonary fibrosis, (Suppl. 97) S-145  
 RCCX module CNV, (Suppl. 97) S-12  
 renal, (Suppl. 97) S-105  
 rituximab, (Suppl. 97) S-121  
 rs16944, (Suppl. 97) S-84  
 systemic, (Suppl. 97) S-1  
 systemic, (Suppl. 97) S-111  
 Takayasu arteritis, (Suppl. 97) S-44  
 tocilizumab, (Suppl. 97) S-44  
 treatment, (Suppl. 97) S-121  
 vaccination, (Suppl. 97) S-89  
 vaccinations, (Suppl. 95) S-21  
 work disability, (Suppl. 97) S-111
- Vitamin D  
 deficiency, 827  
 rheumatoid arthritis, 827